LAS VEGAS, NV, UNITED STATES, March 17, 2023 /EINPresswire.com/ — Rexis Biotech Inc. (“REXIS”) is delighted to announce that, after more than three years of development and clinical trials, its innovative co-crystal formation and drug delivery platform, Fused Polymorph Nano Fiber TM, has received approval for use and distribution in the United States.
Fused Polymorph Nano Fiber TM is a pioneering co-crystal fusing technology that transforms hydrophobic molecules, such as THC and CBD, into hydrophilic, water-soluble molecules. This breakthrough has broad applications across various industries, including prodrug pharmaceutical medications, consumer packaged goods, and research projects.
In the following weeks, Rexis will announce several profitable licensing agreements with both domestic and international corporations that have licensed Fused Polymorph Nano FiberTM. These early adopters of the technology have collaborated closely with the Rexis development team to create several ground-breaking product advancements with the potential to revolutionize the pharmaceutical and consumer packaged goods industries.
Keith Bushfield, Rexis CEO, stated, “We are thrilled to announce the approval of our novel drug delivery platform, Fused Polymorph Nano Fiber TM, for use in the United States. We are also delighted with the overwhelming demand and acceptance of our technology, not only within the scientific community but also among product developers worldwide.”
On Behalf of the Board of Directors of
Rexis Biotech Inc.
This news release may include forward-looking statements that are subject to risks and uncertainties. All statements within, other than statements of historical fact, are to be considered forward looking. Although the Company believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results or developments may differ materially from those in forward-looking statements. Factors that could cause actual results to differ materially from those in forward-looking statements include market prices, exploitation and exploration successes, continued availability of capital and financing, and general economic, market or business conditions. There can be no assurances that such statements will prove accurate and, therefore, readers are advised to rely on their own evaluation of such uncertainties. We do not assume any obligation to update any forward-looking statements except as required under the applicable laws.
About Rexis Biotech Inc.
Rexis is the industry leader and pioneer in developing Hydrophobic Molecule Delivery systems. Leading in the innovation, production and formulation of water based ingredients for use in Pharmaceutical and Consumer Packaged goods industry. Established in 2022, Rexis is building a core mix of proprietary IP used to sustain strong sales models with pharmaceutical licensees, consumer packaged goods manufacturers and clinical research teams.
For more information, please visit: www.rexissystems.com
Statements in this press release have not been evaluated by the Food and Drug Administration. Products or ingredients are not intended to diagnose, treat, cure or prevent any disease.
REXIS BIOTECH – Information Request